Edition:
United Kingdom

AB Science SA (ABS.PA)

ABS.PA on Paris Stock Exchange

8.46EUR
4:35pm GMT
Change (% chg)

€-0.09 (-1.05%)
Prev Close
€8.55
Open
€8.56
Day's High
€8.70
Day's Low
€8.36
Volume
72,402
Avg. Vol
86,018
52-wk High
€18.07
52-wk Low
€7.53

Chart for

About

AB Science SA, also known as AB Science, is a France-based pharmaceutical company specialized in the research, discovery, development and marketing of protein kinase inhibitors (PKIs). It is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer,... (more)

Overall

Beta: 1.61
Market Cap(Mil.): €367.11
Shares Outstanding(Mil.): 40.79
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-AB Science announces publication of preclinical data showing that masitinb is capable of counteracting resistance to oncology treatments

* REG-AB SCIENCE ANNOUNCES THE PUBLICATION OF PRECLINICAL DATA SHOWING THAT MASITINB IS CAPABLE OF COUNTERACTING RESISTANCE TO ONCOLOGY TREATMENTS

21 Nov 2017

BRIEF-AB science announces ‍preclinical data showing protective effect of masitinib

* ‍PRECLINICAL DATA SHOWING PROTECTIVE EFFECT OF MASITINIB ON PERIPHERAL NERVOUS SYSTEM IN ALS PUBLISHED IN JOURNAL OF CLINICAL INVESTIGATION INSIGHT​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

19 Oct 2017

BRIEF-AB Science: CHMP adopts negative opinion for Masitinib marketing authorization

* REG-AB SCIENCE ANNOUNCES THAT CHMP ADOPTED A NEGATIVE OPINION FOR MASITINIB MARKETING AUTHORIZATION IN INDOLENT SYSTEMIC MASTOCYTOSIS AFTER REASSESSMENT

14 Sep 2017

BRIEF-AB Science net loss narrows to 13.5 million euros

* NET LOSS OF 13.5MEUR IN FIRST HALF OF 2017, A DECREASE OF 8.4% AS COMPARED WITH FIRST HALF OF 2016 (14.7MEUR )

31 Aug 2017

BRIEF-AB Science announces issuance of a new european patent

* REG-AB SCIENCE ANNOUNCES ISSUANCE OF A NEW EUROPEAN PATENT FOR PROTECTING THE USE OF MASITINIB IN PANCREATIC CANCER PATIENTS

12 Jul 2017

BRIEF-AB Science presents supportive data from its phase 3 study in severe systemic mastocytosis

* PRESENTS SUPPORTIVE DATA FROM ITS PHASE 3 STUDY IN SEVERE SYSTEMIC MASTOCYTOSIS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

22 Jun 2017

Earnings vs. Estimates